Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:13 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Phase 1 Interventional Results available

Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors

NCT00308165
View directory record Official record
Conditions
Brain Neoplasms, Primary Malignant
Interventions
Convection-Enhanced Delivery, Topotecan
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
1 Year and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 1 Interventional

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

NCT01495663
View directory record Official record
Conditions
Cancer
Interventions
I-131-CLR1404
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Nov 3, 2026, 5:13 AM EST
Recruiting Phase 1 Interventional

DBS for Depression

NCT06096207
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Medtronic SenSight Directional DBS lead
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed Not applicable Interventional Results available

Real-time Effort Driven VENTilator Management

NCT03266016
View directory record Official record
Conditions
Ventilation Therapy; Complications, Diaphragm Disease, Pediatric Respiratory Diseases
Interventions
Computerized Ventilator Protocol, Esophageal Manometry, Respiratory Inductance Plethysmography (RIP), Diaphragm Ultrasound, Maximal Inspiratory Pressure
Other · Diagnostic Test
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
30 Days to 18 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Nov 3, 2026, 5:13 AM EST
Terminated Phase 2 Interventional Results available

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

NCT01523171
View directory record Official record
Conditions
Hematopoietic Neoplasm
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Lorcaserin, Placebo, Cocaine Infusion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 2 Interventional Results available

Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

NCT00064792
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Simvastatin Susp., OraPlus
Drug
Lead sponsor
Forbes Porter, M.D.
NIH
Eligibility
4 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Nov 3, 2026, 5:13 AM EST
Terminated Phase 3 Interventional Results available

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Nov 3, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional Results available

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT03794349
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions
Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
124
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 2 Interventional Results available

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Nov 3, 2026, 5:13 AM EST
Recruiting Not applicable Interventional

OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases

NCT04020276
View directory record Official record
Conditions
Liver Metastases, Stereotactic Body Radiation Therapy, MRI-guided Treatment
Interventions
SBRT
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

NCT01517880
View directory record Official record
Conditions
GNE Myopathy, Hereditary Inclusion Body Myopathy
Interventions
Sialic Acid Extended Release (SA-ER), Placebo
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Nov 3, 2026, 5:13 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485
View directory record Official record
Conditions
COVID-19
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 3, 2026, 5:13 AM EST
Not yet recruiting Phase 2 Interventional

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

NCT07029776
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

NCT02429791
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Nov 3, 2026, 5:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Expanded Game Squad for Neurodiverse Youth

NCT03665415
View directory record Official record
Conditions
Physical Activity, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Health Behavior, Developmental Disorder
Interventions
NDGameSquad
Behavioral
Lead sponsor
Merrimack College
Other
Eligibility
11 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Marblehead, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Nov 3, 2026, 5:13 AM EST
Terminated Phase 2 Interventional Results available

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

NCT03781960
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Abemaciclib, Nivolumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Nov 3, 2026, 5:13 AM EST
Recruiting Phase 3 Interventional

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

NCT05821959
View directory record Official record
Conditions
Sensorineural Hearing Loss, Bilateral
Interventions
AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Combination Product
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 1 Interventional

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

NCT02582359
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
MLN9708, Cytarabine, Daunorubicin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Nov 3, 2026, 5:13 AM EST
Completed Not applicable Interventional Results available

Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

NCT00941915
View directory record Official record
Conditions
Prostate Cancer
Interventions
SBRT Prostate
Radiation
Lead sponsor
Duke University
Other
Eligibility
40 Years to 82 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Nov 3, 2026, 5:13 AM EST
Completed Not applicable Interventional

Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors

NCT03039140
View directory record Official record
Conditions
Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Nov 3, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

NCT05794555
View directory record Official record
Conditions
Cirrhosis, Liver, Portal Hypertension
Interventions
Enhanced Usual Care, Lactulose, Investigator recommended exercise, TeleTai-Chi (virtual)
Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:13 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects

NCT01029015
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry, polysomnography
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Nov 3, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

NCT02932150
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 3, 2026, 5:13 AM EST